India, Aug. 19 -- Moderna, Inc. (MRNA) shares surged $85.84, or 136.34 percent, to $148.80bon Wednesday, after the company and Merck reported positive Phase 3 results for intismeran autogene in combination with KEYTRUDA in patients with resected melanoma.
The stock opened at $116.25 and traded between $114.46 and $163.47 during the session on the Nasdaq. It has traded in a 52-week range of $22.28 to $163.47. Trading volume reached 87.15 million shares, compared with an average daily volume of 6.88 million shares.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, showing statis...